J&J suffers setback over heart-stent price cap in U.K.

07/23/2008 | Bloomberg

The British National Institute for Health and Clinical Excellence has denied an appeal from Johnson & Johnson's Cordis unit against a ruling that limits the price of drug-coated stents to no more than $599 above the cost of bare-metal stents. Drug-eluting devices "will continue to be an important treatment option for patients who would be at high risk of requiring further interventions if a bare-metal stent was used instead," NICE CEO Andrew Dillon said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA